文献速递类风湿关节炎

来氟米特精准医学:DHODH单倍型与血浆特立氟米特浓度的考量及其对类风湿关节炎结局的影响

Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2021-01-01

本研究纳入67例在传统三联治疗应答不足后加用来氟米特的类风湿关节炎患者,探讨DHODH单倍型与血浆特立氟米特浓度和DAS28应答的关系。结果显示,携带DHODH单倍型2者DAS28更高,而特立氟米特总浓度>16 mg/L与游离浓度>35 µg/L分别与DAS28降低0.33和0.32相关,提示总浓度至少16 mg/L可能最大化应答可能性。

要点

  • DHODH单倍型2与来氟米特治疗后DAS28更高相关。
  • 血浆特立氟米特总浓度>16 mg/L与DAS28降低0.33相关。
  • 游离特立氟米特浓度>35 µg/L与DAS28降低0.32相关。

核心结论

  • 特立氟米特浓度和携带DHODH单倍型2与类风湿关节炎患者来氟米特应答相关,总血浆特立氟米特浓度至少16 mg/L可能最大化应答可能性。

研究设计与样本

  • 纳入67例正在服用或即将开始来氟米特的类风湿关节炎患者,这些患者在传统三联治疗应答不足后加用来氟米特。
  • 采集至多5份血浆样本测定总与游离特立氟米特浓度,以DAS28评估疾病活动度,并用线性混合效应模型分析DAS28与协变量的关联。

主要发现

  • 来氟米特启动后DAS28与基线DAS28相关(β=0.70,P<0.001)。
  • 携带DHODH单倍型2者DAS28更高(β=0.56,P=0.01),不携带共享表位者DAS28也更高(β=0.56,P=0.013)。
  • 总与游离血浆特立氟米特浓度升高时DAS28显著降低(P<0.001和P=0.001)。
  • 特立氟米特总浓度>16 mg/L与DAS28降低0.33相关,游离特立氟米特浓度>35 µg/L与DAS28降低0.32相关。

关键数值与推荐

  • 总血浆特立氟米特浓度至少16 mg/L可能最大化来氟米特应答可能性。
  • 特立氟米特总浓度>16 mg/L对应DAS28降低0.33,游离浓度>35 µg/L对应DAS28降低0.32。

临床怎么用

  • 对来氟米特治疗患者可考虑监测血浆特立氟米特总浓度,以16 mg/L作为潜在参考阈值。
  • DHODH单倍型2检测可能有助于识别来氟米特应答不佳风险较高的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Leflunomide is a commonly used disease-modifying drug in the treatment of rheumatoid arthritis (RA). Its effects are mediated via inhibition of dihydroorotate dehydrogenase (DHODH) by its active metabolite teriflunomide, and the pharmacokinetics of teriflunomide are highly variable. Our objective was to examine the association between the DHODH haplotype and plasma teriflunomide concentration with response to leflunomide in patients with RA where leflunomide was added to an existing disease-modifying drug regimen after failure to achieve an adequate response with conventional triple therapy. METHODS: Patients with RA who were taking, or were about to initiate, leflunomide were included. Participant characteristics, including the DHODH haplotype, were determined. Up to 5 plasma samples were collected after leflunomide was initiated for assays of total and free teriflunomide concentration. Disease activity was determined via the 28-joint Disease Activity Score (DAS28). The association between DAS28 scores and patient covariates was determined by linear mixed-effects modeling. RESULTS: A total of 67 patients were included in the study. The DAS28 score after initiation of leflunomide was associated with the baseline DAS28 score (β = 0.70, P < 0.001) and was higher in those who carried the DHODH haplotype 2 (β = 0.56. P = 0.01) and did not carry the shared epitope (β = 0.56, P = 0.013). As total and free plasma teriflunomide concentration increased, the DAS28 score was significantly lower (P < 0.001 and P = 0.001, respectively). When considering threshold concentrations, teriflunomide concentrations >16 mg/liter were associated with a DAS28 score that was 0.33 lower, and when free teriflunomide concentration was >35 µg/liter, the DAS28 score was 0.32 lower. CONCLUSION: Teriflunomide concentration and carriage of the DHODH haplotype 2 are associated with response to leflunomide in patients with RA, and a total plasma teriflunomide concentration of at least 16 mg/liter is needed to maximize the likelihood of response.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Wiese MD, Hopkins AM, King C, et al. Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021. PMID: 32339392. doi:10.1002/acr.24236

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。